SK287096B6 - Použitie (deaminohydroxy)toremifénu na výrobu farmaceutickej kompozície na liečenie klimakterických ochorení u žien počas menopauzy alebo po menopauze - Google Patents
Použitie (deaminohydroxy)toremifénu na výrobu farmaceutickej kompozície na liečenie klimakterických ochorení u žien počas menopauzy alebo po menopauze Download PDFInfo
- Publication number
- SK287096B6 SK287096B6 SK1607-2002A SK16072002A SK287096B6 SK 287096 B6 SK287096 B6 SK 287096B6 SK 16072002 A SK16072002 A SK 16072002A SK 287096 B6 SK287096 B6 SK 287096B6
- Authority
- SK
- Slovakia
- Prior art keywords
- treatment
- menopause
- toremifene
- deaminohydroxy
- pharmaceutical composition
- Prior art date
Links
- LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 title claims abstract description 46
- 230000009245 menopause Effects 0.000 title claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims abstract description 17
- 239000002207 metabolite Substances 0.000 claims abstract description 10
- 150000002148 esters Chemical class 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 13
- 230000001568 sexual effect Effects 0.000 claims description 13
- 229960003969 ospemifene Drugs 0.000 abstract description 33
- 201000001880 Sexual dysfunction Diseases 0.000 abstract description 10
- 231100000872 sexual dysfunction Toxicity 0.000 abstract description 10
- 230000001833 anti-estrogenic effect Effects 0.000 description 14
- 229940011871 estrogen Drugs 0.000 description 14
- 239000000262 estrogen Substances 0.000 description 14
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 14
- 229960004622 raloxifene Drugs 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 230000001076 estrogenic effect Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 239000000328 estrogen antagonist Substances 0.000 description 9
- 230000002357 endometrial effect Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 229940046836 anti-estrogen Drugs 0.000 description 7
- 206010067572 Oestrogenic effect Diseases 0.000 description 6
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 5
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 5
- 229960001603 tamoxifen Drugs 0.000 description 5
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 5
- 206010027304 Menopausal symptoms Diseases 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 229960005026 toremifene Drugs 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 208000004483 Dyspareunia Diseases 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000009164 estrogen replacement therapy Methods 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 238000009595 pap smear Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- TYAXQZQJKSMYBD-IZHYLOQSSA-N 4-[(z)-4-chloro-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol Chemical compound C1=CC(OCCNC)=CC=C1C(\C=1C=CC(O)=CC=1)=C(\CCCl)C1=CC=CC=C1 TYAXQZQJKSMYBD-IZHYLOQSSA-N 0.000 description 1
- 206010006313 Breast tenderness Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 241000287227 Fringillidae Species 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000002834 estrogen receptor modulator Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 208000024309 orgasm disease Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/625,199 US6245819B1 (en) | 2000-07-21 | 2000-07-21 | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
| PCT/FI2001/000414 WO2002007718A1 (en) | 2000-07-21 | 2001-05-02 | Method for the treatment of climacteric disorders in women during or after the menopause |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK16072002A3 SK16072002A3 (sk) | 2003-06-03 |
| SK287096B6 true SK287096B6 (sk) | 2009-12-07 |
Family
ID=24504996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1607-2002A SK287096B6 (sk) | 2000-07-21 | 2001-05-02 | Použitie (deaminohydroxy)toremifénu na výrobu farmaceutickej kompozície na liečenie klimakterických ochorení u žien počas menopauzy alebo po menopauze |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US6245819B1 (de) |
| EP (1) | EP1305014B1 (de) |
| JP (2) | JP5575351B2 (de) |
| KR (1) | KR100880564B1 (de) |
| CN (1) | CN1287775C (de) |
| AT (1) | ATE300289T1 (de) |
| AU (2) | AU5844901A (de) |
| BG (1) | BG65943B1 (de) |
| BR (1) | BR0112659A (de) |
| CA (1) | CA2416480C (de) |
| CY (1) | CY1105370T1 (de) |
| CZ (1) | CZ299439B6 (de) |
| DE (1) | DE60112301T2 (de) |
| DK (1) | DK1305014T3 (de) |
| EE (1) | EE05344B1 (de) |
| ES (1) | ES2241819T3 (de) |
| HK (1) | HK1056694A1 (de) |
| HR (1) | HRP20030024A2 (de) |
| HU (1) | HU229361B1 (de) |
| IL (1) | IL153823A (de) |
| MX (1) | MXPA03000378A (de) |
| NO (1) | NO329954B1 (de) |
| NZ (1) | NZ524181A (de) |
| PL (1) | PL202654B1 (de) |
| PT (1) | PT1305014E (de) |
| RU (1) | RU2268035C2 (de) |
| SI (1) | SI1305014T1 (de) |
| SK (1) | SK287096B6 (de) |
| UA (1) | UA74386C2 (de) |
| WO (1) | WO2002007718A1 (de) |
| ZA (1) | ZA200300342B (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
| AU2001261244B2 (en) * | 2000-05-09 | 2006-08-03 | Nitromed, Inc. | Infrared thermography and methods of use |
| US6245819B1 (en) * | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
| WO2003103649A1 (en) * | 2002-06-06 | 2003-12-18 | Hormos Medical Corporation | Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women |
| JP2006515276A (ja) * | 2002-10-22 | 2006-05-25 | オスコテック株式会社 | 骨粗鬆症の予防及び治療効果を有するフラン誘導体並びにこれを含む薬学的組成物 |
| US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
| US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
| US8642079B2 (en) * | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
| US20050187302A1 (en) * | 2004-02-23 | 2005-08-25 | Hormos Medical Corporation | Method for treatment or prevention of osteoporosis in individuals with high bone turnover |
| AU2005237274B2 (en) * | 2004-05-04 | 2011-02-17 | Hormos Medical Ltd | Novel oral formulations of ospemifene |
| US8758821B2 (en) | 2004-05-04 | 2014-06-24 | Hormos Medical Ltd. | Oral formulations of ospemifene |
| KR100734942B1 (ko) | 2007-01-02 | 2007-07-03 | 김재현 | 여성 갱년기 증후군에 유효한 건강기능식품 조성물 |
| SI2121553T1 (sl) | 2007-02-14 | 2012-11-30 | Hormos Medical Ltd | Postopek za pripravo terapevtsko uporabnih trifenilbutenskih derivatov |
| US7504530B2 (en) * | 2007-02-14 | 2009-03-17 | Hormos Medical Ltd. | Methods for the preparation of fispemifene from ospemifene |
| US20080293683A1 (en) * | 2007-05-24 | 2008-11-27 | University Of Kansas Medical Center | Hormone Replacement Therapy |
| RU2535112C2 (ru) * | 2012-09-19 | 2014-12-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия министерства здравоохранения и социального развития" | Способ лечения климактерических и урогенитальных расстройств у женщин в постменопаузе на фоне гипотириоза |
| US9321712B2 (en) | 2012-10-19 | 2016-04-26 | Fermion Oy | Process for the preparation of ospemifene |
| ES2960344T3 (es) | 2015-03-10 | 2024-03-04 | Shionogi Inc | Dispersiones sólidas que comprenden ospemifeno |
| WO2016149675A1 (en) | 2015-03-19 | 2016-09-22 | Epstein Wendy Anne | Compounds and forms of treatment for female sexual disorders |
| RU2636619C1 (ru) * | 2017-02-20 | 2017-11-24 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации | Способ лечения вагинальной атрофии у женщин в постменопаузе с учетом состояния эпителия и микробиоценоза влагалища |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352699A (en) | 1992-04-30 | 1994-10-04 | University Of Massachusetts Medical Center | Use of retinioc acid to treat vaginal atrophy |
| US5461064A (en) * | 1993-12-21 | 1995-10-24 | Eli Lilly And Company | Methods of inhibiting atrophy of the skin and vagina |
| GB9418067D0 (en) * | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
| US5747059A (en) | 1996-01-11 | 1998-05-05 | Novo Nordisk A/S | Atrophy of skin/mucous membrane |
| GB9604577D0 (en) * | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
| CO5271697A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
| PL357163A1 (en) | 2000-01-28 | 2004-07-26 | Endorecherche, Inc. | Selective estrogen receptor modulators in combination with estrogens |
| US20010034340A1 (en) | 2000-03-20 | 2001-10-25 | American Home Products Corporation | Hormone replacement therapy |
| US6245819B1 (en) * | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
-
2000
- 2000-07-21 US US09/625,199 patent/US6245819B1/en active Active
-
2001
- 2001-02-05 UA UA2003021522A patent/UA74386C2/uk unknown
- 2001-05-02 SK SK1607-2002A patent/SK287096B6/sk not_active IP Right Cessation
- 2001-05-02 WO PCT/FI2001/000414 patent/WO2002007718A1/en active IP Right Grant
- 2001-05-02 HU HU0301791A patent/HU229361B1/hu unknown
- 2001-05-02 CN CNB018130194A patent/CN1287775C/zh not_active Expired - Lifetime
- 2001-05-02 JP JP2002513454A patent/JP5575351B2/ja not_active Expired - Lifetime
- 2001-05-02 NZ NZ524181A patent/NZ524181A/en not_active IP Right Cessation
- 2001-05-02 IL IL153823A patent/IL153823A/en active IP Right Grant
- 2001-05-02 PL PL359506A patent/PL202654B1/pl unknown
- 2001-05-02 DE DE60112301T patent/DE60112301T2/de not_active Expired - Lifetime
- 2001-05-02 EE EEP200300031A patent/EE05344B1/xx unknown
- 2001-05-02 PT PT01931746T patent/PT1305014E/pt unknown
- 2001-05-02 AT AT01931746T patent/ATE300289T1/de active
- 2001-05-02 AU AU5844901A patent/AU5844901A/xx active Pending
- 2001-05-02 CZ CZ20030026A patent/CZ299439B6/cs not_active IP Right Cessation
- 2001-05-02 EP EP01931746A patent/EP1305014B1/de not_active Expired - Lifetime
- 2001-05-02 AU AU2001258449A patent/AU2001258449B2/en not_active Expired
- 2001-05-02 RU RU2003105159/14A patent/RU2268035C2/ru active
- 2001-05-02 ES ES01931746T patent/ES2241819T3/es not_active Expired - Lifetime
- 2001-05-02 BR BR0112659-8A patent/BR0112659A/pt not_active Application Discontinuation
- 2001-05-02 DK DK01931746T patent/DK1305014T3/da active
- 2001-05-02 CA CA002416480A patent/CA2416480C/en not_active Expired - Lifetime
- 2001-05-02 MX MXPA03000378A patent/MXPA03000378A/es active IP Right Grant
- 2001-05-02 KR KR1020027015576A patent/KR100880564B1/ko active IP Right Grant
- 2001-05-02 SI SI200130410T patent/SI1305014T1/sl unknown
-
2002
- 2002-06-06 US US10/162,708 patent/US6984665B2/en not_active Expired - Lifetime
-
2003
- 2003-01-13 ZA ZA200300342A patent/ZA200300342B/en unknown
- 2003-01-17 HR HR20030024A patent/HRP20030024A2/xx not_active Application Discontinuation
- 2003-01-17 BG BG107472A patent/BG65943B1/bg unknown
- 2003-01-20 NO NO20030273A patent/NO329954B1/no not_active IP Right Cessation
- 2003-12-17 HK HK03109192A patent/HK1056694A1/xx not_active IP Right Cessation
-
2005
- 2005-08-11 US US11/201,098 patent/US20050272825A1/en not_active Abandoned
- 2005-10-26 CY CY20051101313T patent/CY1105370T1/el unknown
-
2010
- 2010-07-15 US US12/837,292 patent/US9566252B2/en not_active Expired - Lifetime
-
2012
- 2012-10-25 JP JP2012235543A patent/JP5629746B2/ja not_active Expired - Lifetime
-
2014
- 2014-01-24 US US14/163,757 patent/US20140142195A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5629746B2 (ja) | 閉経期または閉経後の女性における更年期障害の治療方法 | |
| AU2001258449A1 (en) | Method for the treatment of climacteric disorders in women during or after the menopause | |
| NO20150487L (no) | Fremgangsmåte for inhibering av atrofi eller for behandling eller forhindring av atrofi-relaterte symptomer i kvinner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Patent expired |
Expiry date: 20210502 |